Back to Nephrology
Nephrologyv2019Evidence-Based

International IgA Nephropathy Prediction Tool

Predicts risk of 50% decline in eGFR or end-stage kidney disease in patients with IgA nephropathy. This validated prediction tool was developed using an international multi-ethnic cohort of 2,781 patients with biopsy-proven idiopathic IgA nephropathy. The tool uses clinical, laboratory, and histological parameters available at biopsy to provide risk estimates for kidney function decline. Two versions are available: one including race/ethnicity and one without race. The tool is endorsed by the 2021 KDIGO guidelines as the preferred method to predict kidney outcomes in IgA nephropathy patients. It facilitates clinical decision-making, patient counseling, and clinical trial enrollment by stratifying patients based on their risk of progressive kidney disease.

Clinical Input Parameters

years
Range: 18 — 65 years
mL/min/1.73m²
Range: 5 — 150 mL/min/1.73m²
mmHg
Range: 60 — 140 mmHg
g/day
Range: 0.001 — 15 g/day
score
Range: 0 — 1 score
score
Range: 0 — 1 score
score
Range: 0 — 1 score
score
Range: 0 — 2 score
Clinical Assessment
Awaiting Parameters
risk percentage
—%
Ready to Calculate

Awaiting Clinical Input

Enter the clinical input parameters on the left and click Run Clinical Assessment to evaluate this medical calculator with deterministic clinical scoring.

Open in Web App
Clinical decision support tool for licensed medical practitioners. Confirm independently before prescribing or clinical action.

When & Why to Use

The International IgA Nephropathy Prediction Tool is utilized in clinical practice for risk stratification, diagnostic probability estimation, and treatment decision-making within nephrology.

Use this tool during initial patient intake, emergency department workup, or bedside assessment when objective clinical scoring is required to guide management or admission decisions.

Clinical Formula & Scoring Logic

Risk calculation uses transformed variables: sqrt(eGFR) - 8.8, ln(urine protein + 0.26), (MAP - 100)/15, and MEST scores with specific coefficients for race-inclusive and race-free models

Clinical Pearls & Practice Notes

  • The tool was developed using an international multi-ethnic cohort of 2,781 patients with biopsy-proven IgA nephropathy
  • Two prediction models available: one including race/ethnicity and one race-free model
  • Endorsed by 2021 KDIGO guidelines as preferred method for risk prediction in IgA nephropathy
  • Age range: 18-65 years at time of biopsy for adult version
  • Oxford MEST scores required: M (mesangial), E (endocapillary), S (segmental), T (interstitial fibrosis)
  • eGFR should be calculated using CKD-EPI equation when possible
  • Mean arterial pressure = (2 × diastolic + systolic) / 3
  • 24-hour urine protein preferred; spot urine protein-to-creatinine ratio acceptable alternative
  • RASB includes ACE inhibitors and angiotensin receptor blockers
  • Immunosuppression includes corticosteroids, mycophenolate, cyclophosphamide, etc.
  • Race parameter is optional; race-free model performs similarly
  • Tool validated in multiple international cohorts with good discrimination (C-statistic ~0.72)
  • Risk estimates are for composite outcome of 50% eGFR decline or ESKD
  • Regular recalculation recommended as clinical parameters change
  • Not validated in children; pediatric version uses 30% eGFR decline endpoint
  • Consider local clinical context and patient preferences in treatment decisions
  • Tool assists but does not replace clinical judgment
  • Useful for patient counseling, treatment planning, and clinical trial enrollment

Evidence & Literature Citations

  1. Barbour SJ, Coppo R, Zhang H, Liu ZH, Suzuki Y, Matsuzaki K, et al. Evaluating a New International Risk-Prediction Tool in IgA Nephropathy. JAMA Intern Med. 2019 Jul 1;179(7):942-952. doi: 10.1001/jamainternmed.2019.0600.
  2. Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group. KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney Int. 2021 Oct;100(4S):S1-S276. doi: 10.1016/j.kint.2021.05.021.
  3. Zhang J, Huang B, Liu Z, Wang X, Xie M, Guo R, et al. External validation of the International IgA Nephropathy Prediction Tool. Clin J Am Soc Nephrol. 2020 Jul 7;15(7):1112-1120. doi: 10.2215/CJN.16021219.

Score Interpretation Ranges

Very Low Risk0 – 10 pts

5-year risk <10%

Low Risk10 – 25 pts

5-year risk 10-25%

Moderate Risk25 – 50 pts

5-year risk 25-50%

High Risk50 – 75 pts

5-year risk 50-75%

Very High Risk75 – 100 pts

5-year risk >75%

Need Clinical Suite Access?

Run this calculator with patient history, laboratory integration, and drug interaction safety checks on the DexaMed clinician app.

Open in Web App

Clinical Decision Support (CDS) Notice & Legal Disclaimer

This medical calculator and its scoring interpretation are provided strictly for licensed healthcare professionals and medical trainees as an educational and clinical decision support instrument. It does not replace independent clinical judgment, comprehensive patient history, physical examination, or attending physician oversight. Not FDA-cleared as an autonomous diagnostic medical device. Read the full DexaMed Medical Disclaimer.